A team of researchers at the University of Pittsburgh has made a discovery that can change the way of changing and preventing ovarian cancer. The study suggests that a specific type of high -risk cells found in the auxiliary tissue of fallopian tubes can play an important role in the development of high -range ovarian cancer (HGSOC), which is the most common and most deadly form of ovarian cancer.

A major success in ovarian cancer research

Ovarian cancer is one of the most deadly gynecological cancer, in which more than 12,000 women have lost their lives for illness every year in the United States. The disease is particularly challenging because it often becomes undesirable until it reaches an advanced stage, making treatment less effective. Symptoms such as blotting, pelvic pain and persistent urination are often unclear and are easily incorrect for other conditions. This makes initial identity important, yet existing screening methods, including ultrasound and CA -125 blood tests, are not always reliable.

Despite its high mortality rate, the strategy of prevention for ovarian cancer is limited. The most effective preventive measures for high-risk women are disease-related surgery-rebuilding the insensible and fallopian tubes-which significantly reduces the risk of disease growth. However, this is an aggressive and life-transit process, which requires the need for alternative preventive strategies.

Dr, an associate professor of deadly hematology and medical oncology at Pittsburgh University. Lan Cofman emphasized the importance of this discovery. “Understanding how to improve patient results in the form of ovarian cancer is important. So far, very little focus has been focused on the auxiliary tissue around the cancer cells,” Cofman explained. “This study attracts our attention to the role of fallopian tube stroma and how it contributes to the development of tumors.”

The role of fallopian tube stroma in cancer development

The new study published in Journal Cancer Discovery, auxiliary connective tissue in fallopian tubes, focuses on stroma. Traditionally, researchers have focused on epithelial cells, which change cancer and lead to HGSOC. However, this study suggests that a type of mesencimal stem cell (MSCs), which usually supports healthy tissue growth and repair, can turn and help cancer growth.

Dr. Cofman and his team identified one of these MSCs, which they named “High-Nisk MSCS” (HRMSCS). These cells were also present in women without cancer, but were more common in people with high risk due to aging or factors such as BRCA gene mutations. Researchers found that these high -risk MSCs create a microelement that supports the growth of cancer cells.

How high -risk MSCs trigger cancer formation

The study showed that when high -risk MScs interact with healthy epithelial cells in fallopian tubes, they can promote DNA damage, which is known as serous tubal intrapithelial carcinoma (STIC). These lesions often develop in fully developed HGSOC tumors. This discovery is important because it suggests that ovarian cancer is not fully produced by genetic mutations in epithelial cells, but also by changes in the surrounding stromal tissue.

“These high -risk MSCs promote DNA damage in epithelial cells and then help those mutated cells survive,” Kofman explained. “This is the perfect storm for the initiation of cancer.”

The study also found that high -risk MSc encourages the development of tumors and increases the resistance to chemotherapy, making the treatment more challenging. This insight is particularly important because chemotherapy resistance is a major obstacle in effective treatment of ovarian cancer. Many patients initially respond to treatment, but later relaxes are experienced due to the existence of resistant cancer cells.

A major protein behind the development of cancer

Further investigation revealed that high -risk MSc has reduced the level of an antioxidant called AMP Kinase. This damage increases the protein levels known as WT1, which triggers DNA-damaging compounds. The WT1 is already known to play a role in various cancer, and its increased activity in the presence of high -risk MSc strengthens the stromal microement and the link between the development of ovarian cancer.

Possible discovery for initial identification and prevention opens new possibilities to detect and prevent ovarian cancer at an early stage. Since high -risk MSCs release specific compounds in the bloodstream, they can serve as a biomarker for early detection. Identifying these biomarkers can help doctors to diagnose ovarian cancer long before the current methods permission. Initial detection greatly improves the survival rate, as treatment is more effective when the cancer is caught before spreading.

Additionally, drugs promoting AMP kinase levels can potentially prevent or reversed early cancer -causing changes in the fallopian tube stroma. Such treatment can provide a non-invasive option for women at high risk for surgical removal of ovaries. This will be a game-chain in prevention of ovarian cancer, which offers women more options beyond harsh surgical intervention.

“This is the first report that stromal changes in the fallopian tube actually play a direct role in the initiation of ovarian cancer,” Cofman said. “It also points to a path where we may be able to intervene.”

Future of ovarian cancer research

The study reflects the importance of stromal microelement in the development of cancer and suggests that similar procedures may work in other types of cancer. Understanding these mechanisms can pave the way not only for ovarian cancer but also for other malformations for new treatment approaches. Researchers are now investigating whether the same high -risk MSCs play a role in breast, pancreatic and other aggressive cancer.

The authors of the study said, “To date, biomarkers are not sensitive or specific for HGSOC.” “But by studying the role of the fallopian tube stroma in the formation of cancer, we can highlight better methods to diagnose and prevent this deadly disease.”

This research represents an important step in the fight against ovarian cancer. With further studies and clinical trials, scientists are expected to develop better clinical equipment and targeted treatments that can save thousands of people every year.

Now get the latest news with health and braking news and top headlines worldwide.